Blog
RSS FeedPosted by Michael Wonder on 01 Oct 2025
Imfinzi’s bid for coverage faces Keytruda’s double-edged impact in Korea
30 September 2025 - AstraZeneca's immuno-oncology drug Imfinzi (durvalumab) is attempting to expand its reimbursement coverage, but its competitor, MSD's ...
Posted by Michael Wonder on 26 Sep 2025
HIRA calls for insurance overhaul to ensure access to high cost orphan drugs
26 September 2025 - The Government has proposed that a new health insurance reimbursement system must be designed to ensure ...
Posted by Michael Wonder on 17 Sep 2025
Besremi gains reimbursement as second-line therapy for polycythemia vera in Korea
27 August 2025 - PharmaEssentia Korea announced on Wednesday that Besremi (ropeginterferon alfa-2b), a treatment for polycythemia vera, will be ...
Posted by Michael Wonder on 11 Sep 2025
Doctor treating patients with neurofibromatosis calls for rectifying inconsistent reimbursement standards for Koselugo
26 August 2025 - Last Thursday, people gathered in front of HIRA in Seoul, holding signs that read, “Ignoring doctors' ...
Posted by Michael Wonder on 10 Sep 2025
Review panel backs expanded indications for Keytruda, Dupixent; Imfinzi sent for reconsideration
5 September 2025 - HIRA's Pharmaceutical Reimbursement Evaluation Committee (PREC) has determined that the expanded indications for MSD's immuno-oncology drug ...
Posted by Michael Wonder on 09 Sep 2025
Reimbursement delay leaves Korean patients waiting for Padcev-Keytruda first-line therapy
8 September 2025 - The first-line combination therapy of Padcev and Keytruda for metastatic urothelial carcinoma was not even submitted ...
Posted by Michael Wonder on 02 Sep 2025
Multiple myeloma drug Darzalex to get expanded coverage from September
29 August 2025 - Starting in September, reimbursement for the multiple myeloma treatment Darzalex (daratumumab) will be expanded, reducing the ...
Posted by Michael Wonder on 01 Aug 2025
Reimbursement for oral Fabry disease drug Galafold expanded to first-line treatment
1 August 2025 - Handok's Fabry disease treatment, Galafold (migalastat), will have its insurance coverage criteria expanded to include first-line ...
Posted by Michael Wonder on 17 Jul 2025
Eli Lilly calls out Korea as Verzenio’s $36K cost threatens cure window
17 July 2025 - While Eli Lilly’s Verzenio (abemaciclib) continues to rack up global sales on the strength of its ...
Posted by Michael Wonder on 16 Jul 2025
BeOne bets Tevimbra will beat rivals to PD-1 reimbursement in Korea
15 July 2025 - BeOne Medicines (formerly BeiGene) is doubling down on Korea’s immunotherapy market with an early access push ...
Posted by Michael Wonder on 14 Jul 2025
Astellas Korea renews bid to reimburse targeted gastric cancer drug Vyloy
11 July 2025 - Astellas Korea will reapply for health insurance coverage for its new drug Vyloy (zolbetuximab), a targeted ...
Posted by Michael Wonder on 08 Jul 2025
Drug reimbursement panel approves iptacopan for PNH reimbursement, rejects danicopan over cost concerns
7 March 2025 - The Pharmaceutical Reimbursement Review Committee has made mixed decisions on the two medicines for paroxysmal nocturnal ...
Posted by Michael Wonder on 03 Jul 2025
Bayer's Adempas gets insurance coverage in Korea 11 years after approval
21 May 2025 - The pulmonary arterial hypertension medicine Adempas (riociguat) will be covered by national health insurance starting next ...
Posted by Michael Wonder on 25 Jun 2025
After 9 year wait, Boehringer’s IPF drug Ofev faces generic threat weeks into Korea launch
24 June 2025 - Just two months after German pharma Boehringer Ingelheim secured long-delayed reimbursement for Ofev in Korea, generics ...
Posted by Michael Wonder on 13 Jun 2025
AbbVie’s Epkinly, Eisai’s Lenvima pass reimbursement review; Janssen’s Tecvayli fails
11 June 2025 - AbbVie Korea's Epkinly (epcoritamab), a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma ...